Patents by Inventor Cuixiang Sun

Cuixiang Sun has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230031954
    Abstract: The present invention is directed to methods of treating hematological cancers, such as acute myleiod leukemia, with tetracyclines, or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: August 30, 2017
    Publication date: February 2, 2023
    Inventors: Xiao-Yi Xiao, Jacques P. Dumas, Diana K. Hunt, Cuixiang Sun, Peng Zhao
  • Patent number: 10913712
    Abstract: The present invention is directed to a compound represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof. The variables for Structural Formula (I) are defined herein. Also described is a pharmaceutical composition comprising the compound of Structural Formula (I), or a pharmaceutically acceptable salt thereof, and its therapeutic use.
    Type: Grant
    Filed: April 24, 2019
    Date of Patent: February 9, 2021
    Assignee: Tetraphase Pharmaceuticals, Inc.
    Inventors: Xiao-Yi Xiao, Roger B. Clark, Diana Katharine Hunt, Cuixiang Sun, Magnus P. Ronn, Wu-Yan Zhang, Minsheng He
  • Publication number: 20200048193
    Abstract: The present invention is directed to a compound represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof. The variables for Structural Formula (I) are defined herein. Also described is a pharmaceutical composition comprising the compound of Structural Formula (I), or a pharmaceutically acceptable salt thereof, and its therapeutic use.
    Type: Application
    Filed: April 24, 2019
    Publication date: February 13, 2020
    Inventors: Xiao-Yi Xiao, Roger B. Clark, Diana Hunt, Cuixiang Sun, Magnus P. Ronn, Wu-Yan Zhang, Minsheng He
  • Patent number: 10315992
    Abstract: The present invention is directed to a compound represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof. The variables for Structural Formula (I) are defined herein. Also described is a pharmaceutical composition comprising the compound of Structural Formula (I), or a pharmaceutically acceptable salt thereof, and its therapeutic use.
    Type: Grant
    Filed: January 6, 2017
    Date of Patent: June 11, 2019
    Assignee: Tetraphase Pharmaceuticals, Inc.
    Inventors: Xiao-Yi Xiao, Roger B. Clark, Diana Katharine Hunt, Cuixiang Sun, Magnus P. Ronn, Wu-Yan Zhang, Minsheng He
  • Publication number: 20190077803
    Abstract: The present invention is directed to a compound represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof. The variables for Structural Formula I are defined herein. Also described is a pharmaceutical composition comprising the compound of Structural Formula I and its therapeutic use.
    Type: Application
    Filed: May 2, 2018
    Publication date: March 14, 2019
    Inventors: Chi-Li Chen, Roger B. Clark, Yonghong Deng, Minsheng He, Louis Plamondon, Cuixiang Sun, Xiao-Yi Xiao, Magnus P. Ronn
  • Patent number: 10072007
    Abstract: The present invention is directed to a compound represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof. The variables for Structural Formula I are defined herein. Also described is a pharmaceutical composition comprising the compound of Structural Formula I and its therapeutic use.
    Type: Grant
    Filed: March 24, 2016
    Date of Patent: September 11, 2018
    Assignee: Tetraphase Pharmaceuticals, Inc.
    Inventors: Chi-Li Chen, Roger B. Clark, Yonghong Deng, Minsheng He, Louis Plamondon, Cuixiang Sun, Xiao-Yi Xiao, Magnus P. Ronn
  • Publication number: 20170334841
    Abstract: The present invention is directed to a compound represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof. The variables for Structural Formula (I) are defined herein. Also described is a pharmaceutical composition comprising the compound of Structural Formula (I) and its therapeutic use.
    Type: Application
    Filed: March 1, 2017
    Publication date: November 23, 2017
    Inventors: Yonghong Deng, Louis Plamondon, Cuixiang Sun, Xiao-Yi Xiao, Jingye Zhou, Joyce A. Sutcliffe, Magnus P. Ronn
  • Publication number: 20170305852
    Abstract: The present invention is directed to a compound represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof. The variables for Structural Formula (I) are defined herein. Also described is a pharmaceutical composition comprising the compound of Structural Formula (I), or a pharmaceutically acceptable salt thereof, and its therapeutic use.
    Type: Application
    Filed: January 6, 2017
    Publication date: October 26, 2017
    Inventors: Xiao-Yi Xiao, Roger B. Clark, Diana Katharine Hunt, Cuixiang Sun, Magnus P. Ronn, Wu-Yan Zhang, Minsheng He
  • Patent number: 9624166
    Abstract: The present invention is directed to a compound represented by Structural Formula (1): or a pharmaceutically acceptable salt thereof. The variables for Structural Formula (I) are defined herein. Also described is a pharmaceutical composition comprising the compound of Structural Formula (I) and its therapeutic use.
    Type: Grant
    Filed: August 27, 2010
    Date of Patent: April 18, 2017
    Assignee: Tetraphase Pharmaceuticals, Inc.
    Inventors: Yonghong Deng, Louis Plamondon, Cuixiang Sun, Xiao-Yi Xiao, Jingye Zhou, Joyce A. Sutcliffe, Magnus P. Ronn
  • Patent number: 9573895
    Abstract: The present invention is directed to a compound represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof. The variables for Structural Formula (I) are defined herein. Also described is a pharmaceutical composition comprising the compound of Structural Formula (I), or a pharmaceutically acceptable salt thereof, and its therapeutic use.
    Type: Grant
    Filed: August 30, 2013
    Date of Patent: February 21, 2017
    Assignee: Tetraphase Pharmaceuticals, Inc.
    Inventors: Xiao-Yi Xiao, Roger B. Clark, Diana Katharine Hunt, Cuixiang Sun, Magnus P. Ronn, Wu-Yan Zhang, Minsheng He
  • Publication number: 20170044160
    Abstract: The present invention is directed to a compound represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof. The variables for Structural Formula I are defined herein. Also described is a pharmaceutical composition comprising the compound of Structural Formula I and its therapeutic use.
    Type: Application
    Filed: March 24, 2016
    Publication date: February 16, 2017
    Inventors: Chi-Li Chen, Roger B. Clark, Yonghong Deng, Minsheng He, Louis Plamondon, Cuixiang Sun, Xiao-Yi Xiao, Magnus P. Ronn
  • Publication number: 20160107988
    Abstract: The present invention is directed to a compound represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof. The variables for Structural Formula (I) are defined herein. Also described is a pharmaceutical composition comprising the compound of Structural Formula (I), or a pharmaceutically acceptable salt thereof, and its therapeutic use.
    Type: Application
    Filed: August 30, 2013
    Publication date: April 21, 2016
    Applicant: Tetraphase Pharmaceuticals, Inc.
    Inventors: Xiao-Yi Xiao, Roger B. Clark, Diana Katharine Hunt, Cuixiang Sun, Magnus P. Ronn, Wu-Yan Zhang, Minsheng He
  • Patent number: 9315451
    Abstract: The present invention is directed to a compound represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof. The variables for Structural Formula I are defined herein. Also described is a pharmaceutical composition comprising the compound of Structural Formula I and its therapeutic use.
    Type: Grant
    Filed: May 7, 2010
    Date of Patent: April 19, 2016
    Assignee: TETRAPHASE PHARMACEUTICALS, INC.
    Inventors: Chi-Li Chen, Roger B. Clark, Yonghong Deng, Minsheng He, Louis Plamondon, Cuixiang Sun, Xiao-Yi Xiao, Magnus Rönn
  • Patent number: 8486921
    Abstract: The tetracycline class of antibiotics has played a major role in the treatment of infectious diseases for the past 50 years. However, the increased use of the tetracyclines in human and veterinary medicine has led to resistance among many organisms previously susceptible to tetracycline antibiotics. The modular synthesis of tetracyclines and tetracycline analogs described provides an efficient and enantioselective route to a variety of tetracycline analogs and polycyclines previously inaccessible via earlier tetra-cycline syntheses and semi-synthetic methods. These analogs may be used as anti-microbial agents or anti-pro liferative agents in the treatment of diseases of humans or other animals.
    Type: Grant
    Filed: April 6, 2007
    Date of Patent: July 16, 2013
    Assignee: President and Fellows of Harvard College
    Inventors: Andrew G. Myers, Jason D. Brubaker, Cuixiang Sun, Qiu Wang
  • Publication number: 20120208788
    Abstract: The present invention is directed to a compound represented by Structural Formula (1): or a pharmaceutically acceptable salt thereof. The variables for Structural Formula (I) are defined herein. Also described is a pharmaceutical composition comprising the compound of Structural Formula (I) and its therapeutic use.
    Type: Application
    Filed: August 27, 2010
    Publication date: August 16, 2012
    Inventors: Yonghong Deng, Louis Plamondon, Cuixiang Sun, Xiao-Yi Xiao, Jingye Zhou, Joyce A. Sutcliffe, Magnus P. Ronn
  • Publication number: 20120135968
    Abstract: The present invention is directed to a compound represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof. The variables for Structural Formula I are defined herein. Also described is a pharmaceutical composition comprising the compound of Structural Formula I and its therapeutic use.
    Type: Application
    Filed: May 7, 2010
    Publication date: May 31, 2012
    Inventors: Chi-Li Chen, Roger B. Clark, Yonghong Deng, Minsheng He, Louis Plamondon, Cuixiang Sun, Xiao-Yi Xiao, Magnus Rönn
  • Publication number: 20120115819
    Abstract: The present invention is directed to a compound represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof. The variables for Structural Formula (I) are defined herein. Also described is a pharmaceutical composition comprising the compound of Structural Formula (I) and its therapeutic use.
    Type: Application
    Filed: May 13, 2010
    Publication date: May 10, 2012
    Inventors: Roger B. Clark, Diana Katharine Hunt, Louis Plamondon, Cuixiang Sun, Xiao-Yi Xiao, Magnus P. Rönn
  • Publication number: 20100130451
    Abstract: The tetracycline class of antibiotics has played a major role in the treatment of infectious diseases for the past 50 years. However, the increased use of the tetracyclines in human and veterinary medicine has led to resistance among many organisms previously susceptible to tetracycline antibiotics. The modular synthesis of tetracyclines and tetracycline analogs described provides an efficient and enantioselective route to a variety of tetracycline analogs and polycyclines previously inaccessible via earlier tetra-cycline syntheses and semi-synthetic methods. These analogs may be used as anti-microbial agents or anti-pro liferative agents in the treatment of diseases of humans or other animals.
    Type: Application
    Filed: April 6, 2007
    Publication date: May 27, 2010
    Applicant: Presidents and Fellows of Harvard College
    Inventors: Andrew G. Myers, Jason D. Brubaker, Cuixiang Sun, Qiu Wang